Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

References

• GlobocanColorectal cancer fact sheet 2008 Available from: http://globocan.jarc.fr/factsheets/cancers/colorectal.aspAccessed May 1, 2014
   Google Scholar
• SchmollHJBücheleTGrotheyADempkeWWhere do we stand with 5-fluorouracil?Semin Oncol19992658960510606252
   PubMed Web of Science ®Google Scholar
• de GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol2000182938294710944126
   PubMed Web of Science ®Google Scholar
• GoldbergRMSargentDJMortonRFA randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200422233014665611
   PubMed Web of Science ®Google Scholar
• MiwaMUraMNishidaMDesign of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEur J Cancer199834127412819849491
   PubMed Web of Science ®Google Scholar
• SchüllerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemother Pharmacol20004529129710755317
   PubMed Web of Science ®Google Scholar
• Van CutsemETwelvesCCassidyJXeloda Colorectal Cancer Study GroupOral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyJ Clin Oncol2001194097410611689577
   PubMed Web of Science ®Google Scholar
• Van CutsemEHoffPMHarperPOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsBr J Cancer2004901190119715026800
   PubMed Web of Science ®Google Scholar
• HoffPMAnsariRBatistGComparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyJ Clin Oncol2001192282229211304782
   PubMed Web of Science ®Google Scholar
• TwelvesCWongANowackiMPCapecitabine as adjuvant treatment for stage III colon cancerN Engl J Med20053522696270415987918
   PubMed Web of Science ®Google Scholar
• CassidyJTaberneroJTwelvesCXELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol2004222084209115169795
   PubMed Web of Science ®Google Scholar
• MakatsorisTKalofonosHPAravantinosGHellenic Cooperative Oncology GroupA phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancerInt J Gastrointest Cancer20053510310915879624
   PubMedGoogle Scholar
• ScheithauerWKornekGVRadererMRandomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol2003211307131212663719
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDíaz-RubioERandomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJ Clin Oncol2008262006201218421053
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDíaz-RubioEXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsBr J Cancer2011105586421673685
   PubMed Web of Science ®Google Scholar
• SuenagaMMizunumaNMatsusakaSShinozakiEUenoMYamaguchiTRetrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancerAsia Pac J Clin Oncol20141032232923915091
   PubMed Web of Science ®Google Scholar
• DoiTBokuNKatoKPhase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancerJpn J Clin Oncol20104091392020462981
   PubMed Web of Science ®Google Scholar
• ModestDPLaubenderRPStintzingSEarly tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trialActa Oncol20135295696223244709
   PubMed Web of Science ®Google Scholar
• GiessenCLaubenderRPFischer von WeikersthalLEarly tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trialCancer Sci201310471872423480146
   PubMed Web of Science ®Google Scholar
• SommeijerDWShiQMeyersJPPrognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): individual patient data (IPD) meta-analysis of randomized trials from the ARCAD databaseJ Clin Oncol201331suppl abstr 3520
   Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol2008265326533418854571
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, et al; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol2009201842184719406901
   PubMed Web of Science ®Google Scholar
• McCahillLEYothersGSharifSPrimary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10J Clin Oncol2012303223322822869888
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767268019114685
   PubMed Web of Science ®Google Scholar
• KöhneCHCunninghamDDi CostanzoFClinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3,825 patientsAnn Oncol20021330831711886010
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer2008857959118596824
   PubMed Web of Science ®Google Scholar
• SunWAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyJ Hematol Oncol201256323057939
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med20083582039204918463380
   PubMed Web of Science ®Google Scholar
• GrotheyAHedrickEEMassRDResponse-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107J Clin Oncol20082618318918182660
   PubMed Web of Science ®Google Scholar
• MuroKDoiTBokuNFinal results of bevacizumab (BV) plus capecitabine plus oxaliplatin (XELOX) as first-line therapy in Japanese patients (pts) with metastatic colorectal cancer (MCRC)ASCO-GI2010 abstr 466
   Google Scholar
• IchanteJLAdenisAMalkaDImpact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5-FU + irinotecan + leucovorin (FOLFIRI) or capecitabine + irinotecan (XELIRI) plus bevacizumabESMO2011 abstr 6094
   Google Scholar
• DouillardJYSienaSTaberneroJUnderstanding the value of response and early tumor shrinkage in patients with wild-type KRAS metastatic colorectal cancer treated with panitumumab plus FOLFOXAnn Oncol201223suppl 9 abstr 558p
   Google Scholar
• SchwartzbergLSRiveraFKarthausMPEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancerJ Clin Oncol2014322240224724687833
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol2014151065107525088940
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDLenzHJCALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (MCRC)J Clin Oncol201432suppl abstr LBA3
   Google Scholar